Oligomeric amyloid-β targeted contrast agent for MRI in Mouse Models of Alzheimer's disease

Motivation: Developing imaging tools for these hallmarks is important for the diagnosis and treatment of Alzheimer's disease (AD). Goal(s): To evaluate MRI signal changes in different mouse models and the time-dependent signal changes using our novel gadolinium (Gd)-dodecane tetraacetic acid (DOTA)- ob5 aptamer contrast agent. Approach: We developed an MRI contrast agent by conjugating Gd-DOTA-DNA aptamer called ob5. A total of 10 control mice, 9 3xTg AD mice, and 11 APP/PS/Tau AD mice were included in this study. Results: The signal enhancement peaked around 15 to 20 minutes after injection of the contrast agent. Impact: Our novel contrast agent targeting oAβ has the potential ability to diagnose early AD and monitor the progression of AD.